Dr. Julia E. McGuinness and Dr. Joshua Okay. Sabari talk about the SERENA-6 trial and its outcomes for sufferers with ESR1-mutated HR+/HER2— breast most...
Sufferers with kidney most cancers might profit from scientific trial enrollment, as Dr. Michael Serzan defined whereas discussing early outcomes from the STELLAR-002...